Earnings10:20 AM ETdeveloping · v2

Merck beats Q3 estimates, lifts full-year guidance on Keytruda and Winrevair strength

By BORSA NewsroomPublished Oct 29, 2026, 10:20 AM EDTUpdated Oct 29, 2026, 10:21 AM EDT

Merck beat Q3 estimates with revenue of $18.09B and adjusted EPS of $2.49. Raised full-year guidance. Keytruda sales up 6%, Winrevair up 93%. Stock +4.5%.

Sentimentbullish 80

Strongly bullish · 80 of 100

Impact70

medium · sector-wide

Confidence90%

high confidence · 2 wires

Eventdeveloping

v2 · alerted as breaking

WHAT WE KNOW

Q3 revenue $18.09B vs est $17.35B
Adjusted EPS $2.49 vs est $2.09
Keytruda sales $8.6B (+6%)